• Home
  • Media
  • Sitemap
  • About Us
    • The company
      • Brief Profile
      • Vision
      • Mission 2013
      • Key Milestones
      • Board of Directors
      • Key Management Team
    • Parabolic Drugs in News
    • Media Gallery
  •  Our Business
    • CRAMS
      • Infrastructure
      • Capabilities
      • Our Business Model
      • Why PDL?
      • Contact CRAMS Division
    • APIs
      • Segments
      • Manufacturing Facilities
      • Our Products
      • Accreditations
      • Contact us for APIs
    • R & D
      • R&D Centre, Barwala
      • R&D Lab, Derabassi
      • IPR,QA & QC
  •  Global Presence
    • Market Presence
    • Regulatory Affairs
    • Business Opportunities
      • Contract Research
      • Contract manufacturing
      • Strategic tieups for Global Marketing
  • Human Resources
    • HR at PDL
      • HR Vision
      • HR Goals
    • Work with us
      • Current Openings
      • Upload your CV
  • CSR
    • CSR Initiatives
    • Environmental Concern
    • Health and Safety
  • Investor Relations
    • MD's Address
    • Corporate Governance
    • latest Financial Results
    • Key Financial Indicators
    • Share Holding Pattern
    • Annual Reports
    • Track PDL's Share
    • Research Reports on PDL
    • Contact IR
  • Contact us

Parabolic Drugs Limited(PDL) , founded in 1996, is engaged in the manufacture – including contract manufacture – of APIs and API intermediates. In the year 2011, the company has stepped up in the value chain by foraying into the domestic formulations.

Today PDL has four large scale facilities, three state of the art manufacturing plants at Derabassi, Chachhrauli and Panchkula for over 50 API and API intermediates across antibiotics and non –antibiotic therapies and a Custom Synthesis and R&D centre at Barwala, Haryana.

The company is surging ahead with the right set of drivers –backward and forward integration, world class infrastructure, R&D strengths, diversified product basket across different therapeutic segments and Intellectual Property Rights in the form of DMFs, and Patents for novel processes.

 

 

  •      

Our Profile

From a small contract manufacturer to a reliant partner for the innovator companies

Read more

 

Analyst Corner

Latest News

Parabolic Drugs announces results for 3rd quarter FY 13

Parabolic Drugs announces results for 2nd quarter FY 13

Parabolic Drugs’ Q1 FY 13 sales up 64% to Rs 305.2 crore

Parabolic Drugs’ FY12 sales up 50.3% to Rs 1014.9 crore,Net profit at 51.4 Crore

Parabolic Drugs initiates production at its non antibiotic facility

 




Parabolic Drugs Limited © 2010 | About Us | Contact us | Sitemap |
Privacy Policy